Robust Predictive Model for Different Cancers using Biomarker Proteins

Q3 Medicine
Shruti Jain, Ayodeji Salau
{"title":"Robust Predictive Model for Different Cancers using Biomarker Proteins","authors":"Shruti Jain, Ayodeji Salau","doi":"10.2174/0115743624257352230920091046","DOIUrl":null,"url":null,"abstract":"Background: When analyzing multivariate data, it can be challenging to quantify and pinpoint relationships between a collection of consistent characteristics. Reliable computational prediction of cancer patient's response to treatment based on their clinical and molecular profiles is essential in this era of precision medicine. This is essential in helping doctors choose the least contaminated and most potent restorative therapies that are now available. Better patient monitoring and selection are now possible in clinical trials. Methods: This research proposes a novel robust model to aid in the diagnosis of various cancers induced by biomarker proteins (Protein Kinase B, MAPK, and mammalian Target of Rapamycin). Later, various medications (Perifosine, Wortmannin, and Rapamycin) were proposed to cure cancer. Various studies were carried out to obtain all of the results, which aid in the identification of various types of cancer. The drugs mentioned in this essay help to ward off cancer. Scaling and normalization were carried out using parallel coordinates plots and correlation tests, respectively. The boosted tree method and kNN with multiple distance approaches were also used to generate a solid model. The medical diagnosis system was enhanced by training the boosted tree technique to identify various tumors. A robust model was validated by predicting various values that were displayed against the observed value and agreed with the advised strategy to locate biomarkers to show the value of our method. Results: The results show that the predicted and observed values agree with each other, especially for MAPK pathways. The observed correlation coefficient (r2) is 0.9847 without intercept and 0.9849 with intercept. The precise computational prediction of the reaction of cancer patients to treatment based on the patient's clinical and molecular profiles is vital in the period of exactitude medicine. Conclusion: A robust model was validated by predicting the different values that were plotted with the observed value, which agrees with the results of the proposed technique to uncover biomarkers and shows the effectiveness of our technique.","PeriodicalId":10868,"journal":{"name":"Current Signal Transduction Therapy","volume":"54 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Signal Transduction Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0115743624257352230920091046","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: When analyzing multivariate data, it can be challenging to quantify and pinpoint relationships between a collection of consistent characteristics. Reliable computational prediction of cancer patient's response to treatment based on their clinical and molecular profiles is essential in this era of precision medicine. This is essential in helping doctors choose the least contaminated and most potent restorative therapies that are now available. Better patient monitoring and selection are now possible in clinical trials. Methods: This research proposes a novel robust model to aid in the diagnosis of various cancers induced by biomarker proteins (Protein Kinase B, MAPK, and mammalian Target of Rapamycin). Later, various medications (Perifosine, Wortmannin, and Rapamycin) were proposed to cure cancer. Various studies were carried out to obtain all of the results, which aid in the identification of various types of cancer. The drugs mentioned in this essay help to ward off cancer. Scaling and normalization were carried out using parallel coordinates plots and correlation tests, respectively. The boosted tree method and kNN with multiple distance approaches were also used to generate a solid model. The medical diagnosis system was enhanced by training the boosted tree technique to identify various tumors. A robust model was validated by predicting various values that were displayed against the observed value and agreed with the advised strategy to locate biomarkers to show the value of our method. Results: The results show that the predicted and observed values agree with each other, especially for MAPK pathways. The observed correlation coefficient (r2) is 0.9847 without intercept and 0.9849 with intercept. The precise computational prediction of the reaction of cancer patients to treatment based on the patient's clinical and molecular profiles is vital in the period of exactitude medicine. Conclusion: A robust model was validated by predicting the different values that were plotted with the observed value, which agrees with the results of the proposed technique to uncover biomarkers and shows the effectiveness of our technique.
利用生物标志物蛋白建立不同癌症的稳健预测模型
背景:在分析多变量数据时,量化和确定一致特征集合之间的关系可能具有挑战性。在这个精准医疗的时代,基于临床和分子特征的癌症患者对治疗反应的可靠计算预测是必不可少的。这对于帮助医生选择目前可用的污染最少和最有效的恢复性疗法至关重要。在临床试验中,更好的病人监测和选择是可能的。方法:本研究提出了一个新的稳健模型,以帮助诊断由生物标志物蛋白(蛋白激酶B、MAPK和哺乳动物雷帕霉素靶蛋白)诱导的各种癌症。后来,各种药物(Perifosine, Wortmannin和Rapamycin)被提出用于治疗癌症。进行了各种研究以获得所有的结果,这些结果有助于识别各种类型的癌症。这篇文章中提到的药物有助于预防癌症。分别使用平行坐标图和相关检验进行缩放和归一化。利用增强树方法和多距离kNN方法生成实体模型。通过训练增强树技术,增强了医学诊断系统对各种肿瘤的识别能力。通过预测与观测值相对应的各种值,验证了稳健的模型,并与定位生物标记物的建议策略一致,以显示我们方法的价值。结果:预测值与实测值基本一致,特别是对于MAPK通路。相关系数(r2)无截距为0.9847,有截距为0.9849。在精确医学时代,基于患者的临床和分子特征精确计算预测癌症患者对治疗的反应是至关重要的。结论:通过预测与观测值绘制的不同值,验证了稳健的模型,这与所提出的技术发现生物标志物的结果一致,显示了我们技术的有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.70
自引率
0.00%
发文量
18
审稿时长
>12 weeks
期刊介绍: In recent years a breakthrough has occurred in our understanding of the molecular pathomechanisms of human diseases whereby most of our diseases are related to intra and intercellular communication disorders. The concept of signal transduction therapy has got into the front line of modern drug research, and a multidisciplinary approach is being used to identify and treat signaling disorders. The journal publishes timely in-depth reviews, research article and drug clinical trial studies in the field of signal transduction therapy. Thematic issues are also published to cover selected areas of signal transduction therapy. Coverage of the field includes genomics, proteomics, medicinal chemistry and the relevant diseases involved in signaling e.g. cancer, neurodegenerative and inflammatory diseases. Current Signal Transduction Therapy is an essential journal for all involved in drug design and discovery.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信